	Name of the Issue: Innova Captab Limited		Last update	ed on 15-11-2025
1	Type of Issue	Initial Public offer		
2	Issue Size (Rs. Mn)	5,700.00		
	Fresh Issue (Rs Mn)	3,200.00		
	Offer for Sale (Rs Mn)	2,500.00		
	*Source: Prospectus for the offer dated December 26, 202	23		
3	Grade of issue along with name of the rating agency			
	Name	NA		
	Grade	NA		

4 Subscription Level (Number of times) 39.17*

* All after rejections, removing multiple bids, duplicate bids and Cancelled/withdrawal/duplicate applications/RC 10 & Other than RC 10 bids and after recategorization Source: Post Issue Report

5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges

Particulars	%
(i) On Allotment in the offer (1)	11.12%
(ii) at the end of the 1st Quarter immediately after the listing	13.88%
of the issue (December 31, 2023)	
(iii) at the end of 1st FY (March 31, 2024)	22.71%
(iv) at the end of 2nd FY (March 31, 2025)	20.10%
(v) at the end of 3rd FY (March 31, 2026)*	Not Available

*QIB Holding not disclosed as reporting for the relevant period/fiscal year has not been completed.

(1) Source:Basis of Allotment (Includes allotment to Anchor Investors)

6 Financials of the issuer

			(Rs. in Cores)
Parameters	1st FY (March 31, 2024)	2nd FY (March 31, 2025)	3rd FY (March 31, 2026)*
Income from operations	1,081.31	1,243.68	Not Available
Net Profit for the period	94.35	128.26	Not Available
Paid-up equity share capital	57.23	57.23	Not Available
Reserves excluding revaluation reserves	773.67	902.19	Not Available

*Financials not available as reporting for the relevant years has not been completed.

7 Trading Status

The equity shares of Innova Captab Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")

The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2025)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available

* Trading status not disclosed as the relevant fiscal years have not been completed.

8 Change in Directors of Issuer from the disclosures in the offer document

•	Change in Directors of issuer from the discressives in the other document				
Particulars		Name of Director	Appointed/Resigned		
	(i) at the end of 1st FY (March 31, 2024)	No Change	No Change		
	(ii) at the end of 2nd FY (March 31, 2025)	•	-		
	(iii) at the end of 3rd FY (March 31, 2026)*	-	-		

* Relevant fiscal years have not been completed. Updated till November 15, 2025

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document

(ii) Actual implementation

(iii) Reasons for delay in implementation, if any

Not applicable Not applicable Not applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document

Particular	Total estimated amount / expenditure	Fiscal 2024	Fiscal 2025
Repayment and / or prepayment, in part or in full, of certain outstanding loans of our Company	1,444.00	1,444.00	-
Investment in our Subsidiary, UML, for repayment and / or prepayment in part or full of outstanding loans availed by UML	236.00	236.00	-
Funding our working capital requirements	720.00	100.00	620.00
General corporate purposes	531.09	531.09	=
Total Net Proceeds	2,931.09	2,311.09	620.00
Sourced from the Prospectus for the offer dated December	ber 26, 2023.		
(ii) Actual utilization : B116			(Rs. in Crores)

Particular Unutilised amount Rs crore Original cost (as per the Offer Document) Revised Cost Amount utilised as at the end of the quarter (June **2024)** 1,444.00 Repayment/pre-payment of certain indebtedness 1,444.00 1,444.00 Investment in Subsidiary 236.00 236.00 236.00 Funding Working Capital 720.00 720.00 720.00 General corporate purposes 531.09 542.18 542.18 NIL Total Net Proceeds 2,931.09 2,942.18 2,942.18

Source: Monitoring agency report dated July 25, 2025

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the offer document	No comments
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	

Source: Monitoring agency report dated July 25, 2025

12 Pricing Data
Designated Stock Exchange Issue Price (Rs.)

NSE 448.00

Listing Date 29-Dec-23

Price parameters	At close of listing day- December 29, 2023	At close of listing day- December 29, 2023 At close of 30th calendar day from listing day (2) At close of 90th calendar day from listing day (3) (4)(5) (4)(5) (5)		As at the end of the 1st FY after the listing of the issue (31st March, 2024) (4)		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE ⁽⁵⁾	549.85	549.85 515.90 454.45			588.00	443.25
NIFTY50*(5)	21,731.40	21,731.40 21,352.60 22123.65			22526.60	17312.75
Sectoral Index ⁽⁶⁾	Not comparable to any of the available sectoral indices Not comparable to any of the available sectoral indices					
Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2025) ⁽⁴⁾ As at the end of the 3rd FY after the listing of the issue (31st March, 2026) ⁽¹⁾⁽⁴⁾ (31st March, 2026) ⁽¹⁾⁽⁴⁾					
	Closing price High (during the FY)		Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE ⁽⁵⁾	878.85	1,260.00	421.35	NA	NA	NA
NIFTY50*(5)	23,519.35	26,277.35	21,281.45	NA	NA	NA
Sectoral Index ⁽⁶⁾	Not comparable to any of the available sectoral indices Not comparable to any of the available sectoral indices					

Source: NSE website

- (1) The pricing data is not disclosed as the relevant period/fiscal years have not been completed
- (2) 30th calendar day is taken as listing date plus 29 calendar days
- (3) 90th calendar day is taken as listing date plus 89 calendar days
- (4) High and Low based on intra day prices
- (5) In case of reporting dates falling on a trading holiday, values for the trading day immediately preceding the trading holiday have been considered.
- (6) Comparable Sectoral index is not available

13 Basis for Issue Price

Accounting ratio		Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31, 2024)	At the end of 2nd FY (March 31, 2025)	At the end o 3rd FY (March 31, 2026)*
EPS (Basic)	Issuer:					
	Company (Basic and Diluted)	10	14.16	18.66	22.41	Not Available
	Industry Average - Peer Group-Diluted					
	EPS Torrent Pharmaceuticals Limited	5	36.79	48.94	56.47	Not Available
	Laurus Labs Limited	2	14.64	2.98	6.65	Not Available
	Ajanta Pharma Limited	2	45.89	64.82	73.56	Not Available
	J. B. Chemicals and	2	52.34	35.66	42.45	Not Available
	Pharmaceuticals Limited	-	02.04	66.66	72.70	rvot rivanabil
	NATCO Pharma Limited	2	39.18	77.34	105.26	Not Available
	Eris Lifesciences Limited	1	28.07	28.82	5.68	Not Available
	Indoco Remedies Limited	2	15.42	10.53	-8.46	Not Availabl
	Suven Pharmaceuticals Limited	1	16.16	11.80	10.52	Not Availabl
	Windlas Biotech Limited	5	19.7	27.97	29.19	Not Availabl
	Peer Group: (Consolidated)		29.80	34.32	35.70	Not Available
P/E	Issuer:					
	Company	10	NA #	24.09	39.22	Not Available
	Industry Average - Peer Group					•
	Torrent Pharmaceuticals Limited	5	57.61	53.14	57.28	Not Available
	Laurus Labs Limited	2	25.53	131.66	92.30	Not Available
	Ajanta Pharma Limited	2	42.91	34.42	35.60	Not Available
	J. B. Chemicals and	2	28.61	46.28	38.21	Not Available
	Pharmaceuticals Limited					
	NATCO Pharma Limited	2	19.90	12.31	7.58	Not Availabl
	Eris Lifesciences Limited	1	33.01	29.26	249.38	Not Available
	Indoco Remedies Limited	2	22.74	31.21	-	Not Available
	Suven Pharmaceuticals Limited	1	37.13	57.38	110.25	Not Available
	Windlas Biotech Limited	5	22.04	18.24	35.67	Not Available
	Peer Group: (Consolidated)		32.16	45.99	78.28	
RoNW %	Issuer:					
	Company	10	24.58%	11.35%	13.37%	Not Available
	Industry Average - Peer Group					
	Torrent Pharmaceuticals Limited	5	20.11%	24.15%	25.17%	Not Available
	Laurus Labs Limited	2	19.74%	3.95%	8.01%	Not Available
	Ajanta Pharma Limited	2	17.36%	22.88%	24.28%	Not Available
	J. B. Chemicals and	2	16.54%	18.90%	19.21%	Not Available
	Pharmaceuticals Limited					
	NATCO Pharma Limited	2	14.84%	23.72%	24.79%	Not Available
	Eris Lifesciences Limited	1	17.10%	15.35%	3.08%	Not Available
	Indoco Remedies Limited	2	13.83%	8.74%		Not Available
	Suven Pharmaceuticals Limited	1	23.70%	14.64%	15.79%	Not Available
	Windlas Biotech Limited	5	10.61%	12.93%	12.06%	Not Available
	Peer Group: (Consolidated)		16.05%	16.14%	16.55%	Not Available
NAV per share	Issuer:					
	Company	10	57.60	145.20	167.66	Not Available
	Industry Average - Peer Group		400.07	200 57	00.400	Alex Accellent
	Torrent Pharmaceuticals Limited	5	182.97	202.57	224.29	Not Available
	Laurus Labs Limited	2	74.92	76.27	82.94	Not Available
	Ajanta Pharma Limited J. B. Chemicals and	2 2	267.41	283.31	303.44	Not Available
		2	320.36	188.37	220.54	Not Availabl
	Pharmaceuticals Limited NATCO Pharma Limited	2	264.21	326.79	424.71	Not Available
		<u>2</u> 1	264.21 160.85			Not Availabl Not Availabl
	Eris Lifesciences Limited	•		190.12	184.70	
	Indoco Remedies Limited	2	111.58	120.40	110.79	Not Availabl
	Suven Pharmaceuticals Limited	1	68.16	80.56	44.35	Not Availabl
	Windlas Biotech Limited	5	192.02	216.33	241.31	Not Available
Notes	Peer Group: (Consolidated)		182.50	187.19	204.12	Not Available

^{*} Source: Prospectus for the offer dated December 26, 2023.

[^] Financial information of the company as at or for the financial year ended June 30, 2023

^{**}Not available as the relevant fiscal years have not been completed/information not disclosed

Key ratios for the Company for the three fiscal years stated above are/shall be calculated as follows:

⁽i) Basic earnings per Equity Share are computed in accordance with Indian Accounting Standard 33 'Earnings per Share' for issuer company, notified by the Companies (Indian Accounting Standards) Rules, 2015, as amended.

⁽ii) P/E - Closing Market Price as of relevant fiscal year end on BSE / Basic EPS for relevant fiscal

⁽iii) RoNW - Return on Net worth attributable to the owners of our Company (%) = Restated profit / (loss) for the year attributable to owners of the Company / Net worth attributable to owners of the Company / Net worth attributable to owners of the Company (iv) NAV per share - Networth at the end of the year / Shares Outstanding as of fiscal year end # Not meaningful as the company/companies has/have incurred losses

14 Any other material information

Date	Announcement
29-Dec-23	Listing of equity shares of Innova Captab Limited
11-Jan-24	Company informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/01/2024, inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2023
03-Feb-24	Monitoring Agency Report issues in the respect of the Utilization of the proceeds of the Initial Public Offer ("IPO") of the Company for the quarter ended December 31, 2023
13-Feb-24	Un-Audited (Standalone and Consolidated) Financial Results of the Company for the quarter and nine months ended December 31, 2023.
14-Mar-24	Resignation of Chief Financial Officer (CFO)
21-Mar-24	Intimation Regarding Re-Commencement Of A Manufacturing Facility Of 'Sharon Bio-Medicine Limited' (Material Subsidiary Of The Company)
29-Mar-24	Board Meeting Outcoe-Appointment of CFO & Acquisition of propert in Baddi, Authorization Of Key Managerial Personnel Under Regulation 30(5) Of SEBI LODR, 2015 To Determine Materiality Of An Event Or Information
10-Apr-24	Company minimated that 'Sharon Bio-Medicine Limited (materiar Sucsitiary of the Company), in his board five time of wetting neid on vectors and the surface that a supervised the purchase of a rand and pursuant to Board approval dated April 10th, 2024, Sharon Bio-Medicine Limited has entered into an agreement on April 10, 2024 for purchasing of land admeasuring 4,410 sq. mtr. (5.86 Bigha) situated at Khasra number 1031 & 1032, Central Hope
09-May-24	Town, Selacusi. Debraduo in the State of Ultrakhand. Monitoring Agency Report issues in the respect of the Utilization of the proceeds of the Initial Public Offer ("IPO") of the Company for the quarter ended March 31, 2024
20-May-24	Company informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024, inter alia, to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the Financial Year Ended March 31, 2024
29-May-24	Audited (Standalone and Consolidated) Financial Results of the Company for the F.y. March 31, 2024.
16-Jul-24	Intimation Regarding Change Of Corporate Identification Number Pursuant To The Listing Of Equity Shares Of The Company
23-Jul-24	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
26-Jul-24	Announcement Under Regulation 30 Of SEBI(LODR)- Sharon Bio-Medicine Limited (Material Subsidiary Of The Company) Has Entered Into An Agreement To Purchase Land.
09-Aug-24	Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. August 09, 2024.
09-Aug-24	Quarterly Result For Q1 Of FY 2024 (Consolidated And Standalone)
23-Aug-24	Reg. 34 (1) Annual Report.
24-Aug-24	Business Responsibility and Sustainability Reporting (BRSR)
06-Nov-24	Pursuant To The Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, ('Listing Regulations'), We Wish To Inform You That Our Upcoming Jammu Facility Received 'Drug Manufacturing License' Vide Letter No. CLJK202406146 Dated November 06, 2024 From Government Of Jammu And Kashmir, Department Of Health And Medical Education, Drug Control Organisation, Jammu.
07-Nov-24	Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. November 07, 2024.
07-Nov-24	Statement For Deviation(S) Or Variation(S) Pursuant To Regulation 32 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter And Half Year Ended September 30, 2024
11-Nov-24	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
14-Jan-25	Disclosure under Regulation 30A of LODR - Commencement of operation of New Jammu facility.
20-Jan-25	Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Regularements) Regulations, 2015 -Shifting Of Registered Office Of Sharon Bio-Medicine Limited, Material Subsidiary Of The Company.
20-Jan-25	Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Sale Of Property Of Sharon Bio-Medicine Limited, Material Subsidiary Of The Company.
05-Feb-25	Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. February 05, 2025
05-Feb-25	Approval Of The Un-Audited (Standalone And Consolidated) Financial Results For The Quarter And Nine Months Ended December 31, 2024
11-Feb-25	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
25-Apr-25	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
19-May-25	Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. 19Th May, 2025
19-May-25	Announcement under Regulation 30 (LODR)-Change in Management
19-May-25	Shifting Of Registered Office
06-Jun-25	Gift Of Shares
04-Jul-25	Reg. 34 (1) Annual Report.
04-Jul-25	Business Responsibility and Sustainability Reporting (BRSR)
25-Jul-25	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
07-Aug-25	Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. 07Th August, 2025
20-Aug-25	We Hereby Inform That The Company Has Successfully Completed The Inspection Of Its Cephalosporin Plant, Baddi, Himachal Pradesh Conducted By The United Kingdom Medicines And Healthcare Products Regulatory Agency ('UK-MHRA')
16-Sep-25	We Hereby Inform You That M/S. CARE Ratings Limited, A Credit Rating Agency, Has Revised The Credit Ratings On Banking Facilities Of The Company
20-Oct-25	Recommendation Of GMP Compliance Certificate By The State Service Of Ukraine On Medicines And Drugs Control.
07-Nov-25	Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. 07Th November, 2025
07-Nov-25	Mr. Devendra Ganpatrav Palav, Who Currently Serves As The Chief Executive Officer (CEO) Of Sharon Bio-Medicine Limited, A Material Subsidiary Of The Company, Has Been Redesignated As Manager, In Addition To His Existing Role As CEO.
07-Nov-25	Approval Of The Unaudited (Standalone And Consolidated) Financial Results For The Quarter And Half Year Ended 30Th September, 2025.

Note: The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable. For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and / or www.nseindia.com

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012.

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and / or the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to update the information contained herein except as required by applicable law or regulation.